Voriconazole Accord 
Procedural steps taken and scientific information after the authorisation 
Application 
Scope 
number 
Opinion/ 
Commission 
Product 
Summary 
Notification1 
Decision 
Information 
issued on 
Issued2 / 
affected3  
amended 
on 
IB/0037 
C.I.11.z - Introduction of, or change(s) to, the 
01/02/2024 
n/a 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IA/0036 
B.II.b.3.a - Change in the manufacturing process of 
18/10/2023 
n/a 
the finished or intermediate product - Minor change 
1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions 
are issued for all other procedures. 
2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The 
CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures. 
3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet). 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
in the manufacturing process 
IAIN/0035 
C.I.z - Changes (Safety/Efficacy) of Human and 
13/06/2023 
SmPC and PL 
Veterinary Medicinal Products - Other variation 
IB/0033 
B.II.b.3.z - Change in the manufacturing process of 
31/05/2022 
n/a 
the finished or intermediate product - Other variation 
IB/0032 
C.I.3.z - Change(s) in the SPC, Labelling or PL 
22/04/2022 
27/02/2023 
SmPC 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Other variation 
IA/0031 
A.7 - Administrative change - Deletion of 
11/03/2022 
27/02/2023 
Annex II and 
manufacturing sites 
PL 
IB/0030/G 
This was an application for a group of variations. 
13/01/2022 
03/02/2022 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Page 2/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0029/G 
This was an application for a group of variations. 
07/10/2021 
28/10/2021 
SmPC, Annex 
II and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IB/0028 
B.II.b.3.z - Change in the manufacturing process of 
10/02/2021 
n/a 
the finished or intermediate product - Other variation 
IAIN/0027/G 
This was an application for a group of variations. 
02/07/2020 
05/07/2021 
Annex II and 
Page 3/11 
 
 
 
 
 
 
 
 
 
 
 
 
PL 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
IA/0026/G 
This was an application for a group of variations. 
27/01/2020 
n/a 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
B.III.1.a.2 - Submission of a new/updated or 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0025 
B.I.b.2.e - Change in test procedure for AS or 
16/12/2019 
n/a 
starting material/reagent/intermediate - Other 
changes to a test procedure (including replacement 
or addition) for the AS or a starting 
material/intermediate 
IAIN/0024/G 
This was an application for a group of variations. 
17/09/2019 
n/a 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
Page 4/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.a - Replacement or addition of a 
manufacturing site for the FP - Secondary packaging 
site 
B.II.b.1.b - Replacement or addition of a 
manufacturing site for the FP - Primary packaging 
site 
IA/0023/G 
This was an application for a group of variations. 
23/08/2019 
n/a 
B.II.a.3.b.1 - Changes in the composition 
(excipients) of the finished product - Other excipients 
- Any minor adjustment of the quantitative 
composition of the finished product with respect to 
excipients 
B.II.b.3.a - Change in the manufacturing process of 
the finished or intermediate product - Minor change 
in the manufacturing process 
IAIN/0022 
C.I.3.a - Change(s) in the SPC, Labelling or PL 
07/03/2019 
21/02/2020 
SmPC 
intended to implement the outcome of a procedure 
concerning PSUR or PASS or the outcome of the 
assessment done under A 45/46 - Implementation of 
wording agreed by the competent authority 
T/0021 
Transfer of Marketing Authorisation 
01/02/2019 
20/02/2019 
SmPC, 
Labelling and 
PL 
Page 5/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IAIN/0020/G 
This was an application for a group of variations. 
26/10/2018 
20/02/2019 
Annex II and 
PL 
B.II.b.2.c.1 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Replacement or addition of a manufacturer 
responsible for importation and/or batch release - 
Not including batch control/testing 
B.II.b.2.c.2 - Change to importer, batch release 
arrangements and quality control testing of the FP - 
Including batch control/testing 
IA/0019 
B.II.b.4.a - Change in the batch size (including batch 
08/02/2018 
n/a 
size ranges) of the finished product - Up to 10-fold 
compared to the originally approved batch size 
R/0017 
Renewal of the marketing authorisation. 
14/12/2017 
08/02/2018 
SmPC, Annex 
Based on the review of data on quality, safety and efficacy, 
II, Labelling 
the CHMP considered that the benefit-risk balance of 
and PL 
Voriconazole Accord in the approved indication remains 
favourable and therefore recommended the renewal of the 
marketing authorisation with unlimited validity. 
IB/0018 
C.I.2.a - Change in the SPC, Labelling or PL of a 
05/09/2017 
08/02/2018 
SmPC, 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
Labelling and 
PL 
IA/0016 
B.II.d.1.d - Change in the specification parameters 
11/11/2016 
n/a 
and/or limits of the finished product - Deletion of a 
non-significant specification parameter 
Page 6/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IB/0014 
C.I.11.z - Introduction of, or change(s) to, the 
13/07/2016 
26/06/2017 
Annex II 
obligations and conditions of a marketing 
authorisation, including the RMP - Other variation 
IA/0015 
B.III.1.a.2 - Submission of a new/updated or 
28/06/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IA/0013 
B.III.1.a.2 - Submission of a new/updated or 
28/06/2016 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - Updated certificate 
from an already approved manufacturer 
IB/0012 
C.I.2.a - Change in the SPC, Labelling or PL of a 
14/06/2016 
08/12/2016 
SmPC and PL 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0011 
B.II.b.3.a - Change in the manufacturing process of 
04/05/2016 
n/a 
the finished or intermediate product - Minor change 
in the manufacturing process 
IB/0010 
B.II.f.1.b.1 - Stability of FP - Extension of the shelf 
29/04/2016 
08/12/2016 
SmPC 
life of the finished product - As packaged for sale 
(supported by real time data) 
IB/0009 
C.I.2.a - Change in the SPC, Labelling or PL of a 
27/01/2016 
08/12/2016 
SmPC, Annex 
generic/hybrid/biosimilar products following 
II, Labelling 
Page 7/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
assessment of the same change for the reference 
and PL 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0008/G 
This was an application for a group of variations. 
15/12/2015 
08/12/2016 
SmPC, 
Labelling and 
PL 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
Page 8/11 
 
 
 
 
 
 
 
 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
B.II.e.5.a.1 - Change in pack size of the finished 
product - Change in the number of units (e.g. 
tablets, ampoules, etc.) in a pack - Change within 
the range of the currently approved pack sizes 
IB/0007/G 
This was an application for a group of variations. 
23/11/2015 
09/12/2015 
SmPC and PL 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
Page 9/11 
 
 
 
 
 
 
 
 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IA/0006 
B.III.1.a.1 - Submission of a new/updated or 
13/03/2015 
n/a 
deletion of Ph. Eur. Certificate of Suitability to the 
relevant Ph. Eur. Monograph - New certificate from 
an already approved manufacturer 
PSUSA/3127/
Periodic Safety Update EU Single assessment - 
09/10/2014 
n/a 
PRAC Recommendation - maintenance 
201402 
voriconazole 
IAIN/0004 
B.II.b.2.c.2 - Change to importer, batch release 
20/12/2013 
01/10/2014 
Annex II and 
arrangements and quality control testing of the FP - 
PL 
Page 10/11 
 
 
 
 
 
 
 
 
 
 
 
 
Including batch control/testing 
IB/0003 
To update SmPC section 4.4 to recommend regular 
18/10/2013 
01/10/2014 
SmPC and PL 
dermatologic evaluation. The package leaflet is 
updated accordingly. The PL is also updated to add 
the side effect sunburn. Furthermore, the PI was 
brought in line with the latest QRD template version 
9.0. All changes made are in order to harmonise the 
text with the originator. 
C.I.2.a - Change in the SPC, Labelling or PL of a 
generic/hybrid/biosimilar products following 
assessment of the same change for the reference 
product - Implementation of change(s) for which NO 
new additional data is required to be submitted by 
the MAH 
IAIN/0001 
C.I.8.a - Introduction of or changes to a summary of 
30/08/2013 
n/a 
Pharmacovigilance system - Changes in QPPV 
(including contact details) and/or changes in the 
PSMF location 
Page 11/11 
 
 
 
 
 
 
 
 
 
 
 
 
 
